Howland Capital Management LLC Has $35.98 Million Position in Stryker Corporation $SYK

Howland Capital Management LLC grew its stake in shares of Stryker Corporation (NYSE:SYK) by 2.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 102,127 shares of the medical technology company’s stock after purchasing an additional 2,132 shares during the period. Stryker accounts for approximately 1.4% of Howland Capital Management LLC’s holdings, making the stock its 20th biggest position. Howland Capital Management LLC’s holdings in Stryker were worth $35,984,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in SYK. Norges Bank acquired a new position in shares of Stryker during the fourth quarter valued at about $1,822,272,000. Corient Private Wealth LLC increased its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the period. Alliancebernstein L.P. increased its stake in Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares during the period. Strive Asset Management LLC bought a new stake in Stryker in the third quarter valued at about $227,389,000. Finally, Credit Agricole S A bought a new stake in Stryker in the third quarter valued at about $194,045,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 2.1%

Shares of SYK stock opened at $312.14 on Friday. The firm has a fifty day moving average of $316.40 and a 200-day moving average of $343.97. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a market capitalization of $119.66 billion, a price-to-earnings ratio of 36.13, a P/E/G ratio of 1.93 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analysts Set New Price Targets

SYK has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research note on Friday, May 1st. Canaccord Genuity Group lowered their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Leerink Partners lowered their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, Citigroup lowered their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $395.33.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last quarter. Company insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.